Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496037 | 1.00 | PLAU (0.37) | PLAUNCF1MEN1NPC1MAPT | |
| SCHEMBL22969163 | 0.83 | GABRP (0.39) | PLAUNCF1MEN1KMT2ABACE1 | |
| SCHEMBL29495862 | 0.82 | PLAU (0.37) | PLAUNCF1BACE1 | |
| SCHEMBL24671045 | 0.82 | PLAU (0.37) | PLAUNCF1BACE1 | |
| SCHEMBL29495705 | 0.75 | REV1 (0.35) | PLAUNCF1BACE1 | |
| SCHEMBL24671041 | 0.75 | REV1 (0.35) | PLAUNCF1BACE1 | |
| SCHEMBL21223541 | 0.73 | FGFR1 (0.53) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL27776395 | 0.66 | AHR (0.41) | MEN1NPC1MAPTRAB9AKMT2A | |
| SCHEMBL6644412 | 0.66 | — | — | |
| SCHEMBL21223302 | 0.64 | DHFR (0.60) | NPC1MAPTRAB9ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | NPFFR2, NPFFR1, OPRL1 | PLAU 2215/4885NCF1 280/4885MEN1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.